TT Trane Technologies
Data as of close
Liquid Cooling StocksS&P 500 CompaniesAI Server Stocks
Healthcare · Auto Controls For Regulating Residential & Comml Environments
Trane Technologies (TT) is a healthcare company in the Auto Controls For Regulating Residential & Comml Environments industry, with a market capitalization of $91.4 billion. Shares last traded at $417.49, 17.4% below their 52-week high. Over the past year the stock is down 7.0%. TT trades at a price-to-earnings ratio of 29.01, above the Healthcare median of 26.53. Net profit margin is 13.6%, above the peer median of -1.4%. Revenue grew 7.5% year over year. The shares yield 0.8% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.
TT Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $837M | $3.72 | 29% |
| 2024-12-31 | $758M | $3.32 | 29% |
| 2023-12-31 | $684M | $2.96 | 34% |
| 2022-12-31 | $620M | $2.64 | 35% |
| 2021-12-31 | $561M | $2.32 | 39% |
| 2020-12-31 | $507M | $2.09 | 59% |
| 2019-12-31 | $510M | $2.09 | 36% |
| 2018-12-31 | $480M | $1.92 | 36% |
| 2017-12-31 | $430M | $1.67 | 33% |
| 2016-12-31 | $349M | $1.33 | 24% |
| 2015-12-31 | $303M | $1.13 | 46% |
| 2014-12-31 | $265M | $0.97 | 28% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | $4.74 | 2026-10-29 |
| Q2 2026 | $4.16 | 2026-07-30 |
| Q1 2026 | $2.62 | 2026-04-30 |
| Q4 2025 (derived) | $2.64 | 2026-02-05 |
| FY 2025 | $12.98 | 2026-02-05 |
| Q3 2025 | $3.78 | 2025-10-30 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Healthcare peers
TT vs 14 sector peers (Healthcare), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.07 | 15.33 | 31.9% | -0.12% |
| JNJ | Johnson & Johnson | $640.8B | 39.81 | 6.45 | 16.2% | -1.76% |
| ONC | Beone Medicines Ltd. | $524.6B | 800.05 | 85.59 | 10.7% | -1.72% |
| ABBV | AbbVie | $503.8B | 48.71 | 7.63 | 15.7% | -1.30% |
| MRK | Merck | $356.9B | 112.49 | 5.36 | 4.8% | -2.57% |
| TMO | Thermo Fisher Scientific | $258.8B | 36.59 | 5.46 | 14.9% | +2.28% |
| AMGN | Amgen | $243.1B | 27.80 | 6.38 | 23.0% | -3.41% |
| GILD | Gilead Sciences | $207.8B | — | 6.70 | -12.5% | -1.70% |
| KLAC | KLA Corporation | $205.9B | 39.16 | 14.19 | 36.2% | +3.95% |
| ABT | Abbott Laboratories | $190.6B | 30.37 | 4.22 | 13.9% | -0.78% |
| PFE | Pfizer | $171.2B | 42.46 | 2.69 | 6.3% | -2.18% |
| DHR | Danaher Corporation | $161.9B | 37.37 | 6.32 | 16.9% | +0.86% |
| ISRG | Intuitive Surgical | $152.8B | 51.66 | 13.19 | 25.5% | +0.84% |
| VRTX | Vertex Pharmaceuticals | $134.7B | 33.87 | 10.40 | 30.7% | -6.81% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.